Posted on 21/05/2009 in Pharmaceutical Company Product News Merck is pleased to start launching Tredaptive (ER niacin/laropiprant) in the UK later this year, it has stated.
Intended to help patients with mixed dyslipidemia and primary hypercholesterolemia, the lipid-modifying therapy will also be marketed in Mexico and Germany by the third quarter of 2009.
Currently, the therapy has been permitted in 39 countries and is known under the trademark Cordaptive in some places.
Dr Luciano Rossetti is the senior vice-president and franchise head of the company's atherosclerosis and cardiovascular division.
He commented: "Merck is pleased that we are now able to supply Tredaptive in approved markets and continue our long-standing commitment to help address unmet medical needs in cardiovascular care."
Earlier this year, the company responded to the Food and Drug Administration's review of Singulair, a treatment for asthma and allergic rhinitis.
The regulatory body requested the medication be evaluated as it had been linked with mood changes and suicidal feelings in some patients.
Merck asserted safety was of great importance to the business and it continually reviews post-marketing reports.Other news stories from 21/05/2009
Read more in the Zenopa News Archive
How this news is generated
|
